The Danish MedTech company Centaflow has, by way of a capital injection and conversion of debt, received more than DKK 100m in connection with an investment round.
The investment is made by Haldor Topsoe Holding, the pension fund PKA and a number of private investors.
Copenhagen-based Centaflow is the first company to combine acoustic sensing with advanced Artificial Intelligence to significantly improve the detection rate of Fetal Growth Restriction (FGR).
FGR results in maternal complications, stillbirths and lifelong diseases. Centaflow’s technology has demonstrated the ability to detect significantly more cases than the current methods, enabling healthcare professionals to take appropriate action.
The technology introduces a new disease detection paradigm based on accurate biomarkers, signal analysis and AI interpretation. It has been developed over a period of ten years with strong support from multiple Danish universities and hospitals. A commercial launch is expected to commence in 2022.
The proceeds from the investment round will contribute to the further development and commercialisation of the advanced technology.
Accura advised Centaflow and the majority shareholder Centaflow Holding in connection with the investment round.
For further information, please read the press release.